ifetroban Updated Jul 13
Cumberland is now a pure-play ifetroban development company with ~$100M+ cash post the Apotex sale. The key swing factor is when and how management engages the FDA on a Phase 3 pathway for DMD cardiomyopathy, watch for an FDA meeting announcement or a specific Phase 3 timeline. The stock remains highly speculative with thin liquidity and a mixed analyst consensus (3 Hold, 1 Sell, 2 Strong Sell).
- Ifetroban would be the first therapy specifically indicated for DMD-related heart disease, the leading cause of death in DMD patients, a clear, unmet-need market (source: Pharmacytimes.com, Medthority.com)
- Phase 2 FIGHT DMD data showed high-dose ifetroban improved LVEF by 3.3% overall and 5.4% vs control at 12 months, the first successful Phase 2 targeting DMD cardiac complications (source: Clinicaltrialsarena.com, Clival.com)
- FDA granted Fast Track (Feb 2026), Orphan Drug, and Rare Pediatric Disease designations, offering expedited review, tax credits, and potential priority review voucher (source: Drugs.com, Rarediseaseadvisor.com)
- Cumberland is now a single-asset development-stage company with no commercial revenue, any setback in ifetroban's development would be company-threatening (source: SEC DEFM14A filing)
- Phase 2 FIGHT DMD data came from only 41 patients; the 3.3% LVEF improvement, while positive, is modest and may not translate to a statistically significant Phase 3 result (source: Clival.com, Neurologylive.com)
- No Phase 3 trial has been designed or initiated for any indication, approval is likely 3-5 years away at minimum, with significant dilution risk (CPIX dilution reported as 390%) (source: Fintel.io, MarketBeat)